共 50 条
- [31] Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: Focus on methylphenidate formulations PHARMACOTHERAPY, 2003, 23 (10): : 1281 - 1299
- [32] Response switching process in children with attention-deficit-hyperactivity disorder on the novel continuous performance test DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2008, 50 (06): : 462 - 466
- [33] Executive and motivational processes in adolescents with Attention-Deficit-Hyperactivity Disorder (ADHD) Behavioral and Brain Functions, 1
- [35] Validation of attention-deficit-hyperactivity disorder subtypes among Taiwanese children using neuropsychological functioning AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2008, 42 (06): : 526 - 535
- [36] Pharmacokinetics of a Guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder PHARMACOTHERAPY, 2007, 27 (09): : 1253 - 1262
- [37] Co-occurrence of developmental delays among preschool children with attention-deficit-hyperactivity disorder DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2006, 48 (06): : 483 - 488
- [38] Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2007, 49 (07): : 498 - 502
- [39] Essential fatty acids and attention-deficit-hyperactivity disorder: a systematic review DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2009, 51 (08): : 580 - 592
- [40] Does attention-deficit-hyperactivity disorder exacerbate executive dysfunction in children with neurofibromatosis type 1? DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2012, 54 (10): : 898 - 904